Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Jun 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-06-10

Reporting Person: SCHEIBLER LUKAS (CHIEF INNOVATION OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-10	Common Stock	S	3417	$60.00	Disposed	26651	Direct

Footnotes

F1: Includes 778 shares from 04/30/21 ESPP Purchase.

F2: This is a scheduled sale from 10B5-1 trading plan.